Hepatitis C virus treatment for prevention among people who inject drugs: modelling treatment scale-up in the age of direct-acting antivirals

Natasha Martin, Peter Vickerman, Jason Grebely, Margaret Hellard, Sharon Hutchinson, Viviane Lima, Graham Foster, John Dillon, David Goldberg, Gregory Dore, Matthew Hickman

Research output: Contribution to journalArticle (Academic Journal)peer-review

81 Citations (Scopus)

Abstract

BACKGROUND: Substantial reductions in HCV prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings. METHODS: A dynamic HCV transmission model was parameterized to three chronic HCV prevalence settings: Edinburgh, UK (25%); Melbourne, Australia (50%); Vancouver, Canada (65%). Using realistic scenarios of future DAAs (90% sustained viral response, 12 weeks duration, available 2015), we projected the treatment rates required to reduce chronic HCV prevalence by half or three-quarters within 15 years. RESULTS: Current HCV treatment rates may minimally impact prevalence in Melbourne and Vancouver (
Original languageEnglish
Pages (from-to)1599
Number of pages12
JournalHepatology
Volume58
Issue number5
Early online date26 Aug 2013
DOIs
Publication statusPublished - 2013

Bibliographical note

Copyright © 2013 American Association for the Study of Liver Diseases.

Fingerprint Dive into the research topics of 'Hepatitis C virus treatment for prevention among people who inject drugs: modelling treatment scale-up in the age of direct-acting antivirals'. Together they form a unique fingerprint.

Cite this